News

Ascendis Pharma Reports First Quarter 2025 Financial Results
Q1 2025 revenue of €44.7 million for YORVIPATH® and €51.3 million for SKYTROFA® - TransCon™ CNP NDA submitted in Q1 2025; MAA ...
Harvard Business Review17h
In Uncertain Times, Ask These Questions Before You Make a Decision
Find new ideas and classic advice on strategy, innovation and leadership, for global leaders from the world's best business and management experts.